17-Alpha-Hydroxyprogesterone Caproate for the Prevention of Preterm Birth in Women With Prior Preterm Birth and a Short Cervical Length

被引:1
|
作者
Berghella, Vincenzo [1 ]
Figueroa, Dana
Szychowski, Jeff M.
Owen, John
Hankins, Gary D. V.
Iams, Jay D.
Sheffield, Jeanne S.
Perez-Delboy, Annette
Wing, Deborah A.
Guzman, Edwin R.
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Obstet & Gynecol, Div Maternal Fetal Med, Philadelphia, PA 19107 USA
关键词
D O I
10.1097/OGX.0b013e3181f07822
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The primary risk factors for recurrent spontaneous preterm birth (SPTB) are a history of SPTB and a short cervical length (CL) found on second trimester transvaginal ultrasound (TVU). In women with prior SPTB or a short CL, the most frequently used interventions to prevent preterm birth (PTB) are cerclage and progesterone supplementation. It is unclear whether the effects of the progesterone agent 17-alpha-hydroxyprogesterone caproate (17P) are additive in women with both primary risk factors. It is also unclear whether 17P is beneficial for women with a prior SPTB and a short CL not undergoing TVU-indicated cerclage. The aim of this study was to evaluate the effect of 17P for the prevention of PTB in pregnant women with prior SPTB, and a short CL, with and without TVU-indicated cerclage. The study was a secondary analysis of a randomized controlled trial sponsored by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, evaluating cerclage for singleton women with prior SPTB (17-33 6/7 weeks), and CL < 25 mm between 16 and 22 6/7 weeks. The trial was conducted by 15 US clinical centers from 2003 through 2007. The women available for the final analysis were randomized to cerclage (n = 148) or no cerclage (n = 152). The primary study outcome was the effect of 17P on PTB < 35 weeks' gestation. The cerclage and no-cerclage groups were analyzed separately. The data showed that 17P had no effect on PTB < 35 weeks in women with or without cerclage (P = 0.64; P = 0.51, respectively). The use of 17P in the no-cerclage group significantly lowered the odds of PTB < 24 weeks (odds ratio [OR], 0.08; P = 0.0022) and perinatal death (OR, 0.14; P = 0.0029). These findings suggest that the use of 17P in women with prior SPTB who underwent TVU-indicated cerclage for short CL < 25 mm provides no additive benefit for prevention of PTB < 35 weeks. In women with these primary risk factors who did not receive cerclage, 17P was associated with reduced previable birth and perinatal mortality.
引用
收藏
页码:477 / 478
页数:2
相关论文
共 50 条
  • [1] 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length
    Berghella, Vincenzo
    Figueroa, Dana
    Szychowski, Jeff M.
    Owen, John
    Hankins, Gary D. V.
    Iams, Jay D.
    Sheffield, Jeanne S.
    Perez-Delboy, Annette
    Wing, Deborah A.
    Guzman, Edwin R.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2010, 202 (04) : 351.e1 - 351.e6
  • [2] 17-Alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length
    Berghella, Vincenzo
    Figueroa, Dana
    Szychowski, Jeff
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (06) : S7 - S7
  • [3] Effect of 17-alpha-hydroxyprogesterone caproate injections on rate of cervical length change in women with a history of prior preterm birth
    Ibrahim, Sherrine
    Lynch, Courtney
    Walker, Hetty
    Rodewald, Katherine
    Iams, Jay
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2013, 208 (01) : S225 - S225
  • [4] 17-alpha hydroxyprogesterone caproate for the prevention of preterm birth
    Gupta, Simi
    Roman, Ashley S.
    WOMENS HEALTH, 2012, 8 (01) : 21 - 30
  • [5] Preventing recurrent preterm birth with 125 mg of 17-alpha-hydroxyprogesterone caproate
    Fukuda, Toma
    Kyozuka, Hyo
    Murata, Tsuyoshi
    Yasuda, Shun
    Yamaguchi, Akiko
    Fujimori, Keiya
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2021, 47 (09) : 3119 - 3126
  • [6] The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length
    Romero, Julie
    Rebarber, Andrei
    Saltzman, Daniel H.
    Schwartz, Rachel
    Peress, Danielle
    Fox, Nathan S.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2012, 207 (01)
  • [7] The role of 17 alpha-hydroxyprogesterone caproate in the prevention of preterm birth
    Meis, Paul J.
    WOMENS HEALTH, 2006, 2 (06) : 819 - 824
  • [8] 17 α-Hydroxyprogesterone Caproate (Makena™)In the Prevention of Preterm Birth
    Emma D. Deeks
    Pediatric Drugs, 2011, 13 : 337 - 345
  • [9] 17 α-Hydroxyprogesterone Caproate (Makena™) In the Prevention of Preterm Birth
    Deeks, Emma D.
    PEDIATRIC DRUGS, 2011, 13 (05) : 337 - 345
  • [10] Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: a critical examination of efficacy and safety
    O'Brien, John M.
    Lewis, David F.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2016, 214 (01) : 45 - 56